



Elan Drug Technologies
Monksland, Athlone, Co Westmeath, Ireland
Tel: +353 1 709 4046

3500 Horizon Dr., King of Prussia, PA 19406
Tel: +1 610 313 7044
Web: www.elan.com/EDT

Vital Statistics

Year Founded: 1969

Number of Employees: 700

Annual Revenues: \$286 million (drug technology group)

Key Personnel: Shane Cooke, Executive Vice President Elan and Head of Elan Drug Technologies; Peter Thornton, SVP, Head of Product, Technology and Business Development; James L Botkin, Executive Vice President, Head of Operations.

Who We Are

ELAN FOCUSES ON PRODUCT DEVELOPMENT, scale-up and manufacturing to address drug optimization challenges of the pharmaceutical industry. Elan's production facilities in Ireland and the US have manufactured and packaged finished solid oral pharmaceutical products for clients for over 30 years. With over 220,000 sq ft of dedicated cGMP grade facilities, Elan has a proven track-record with over 20 products optimised and manufactured for clients in over 90 countries. Solid oral capacity is 3 billion units annually. The US facility also has a DEA Schedule II license to manufacture controlled substances. As a global supplier of ethical pharmaceuticals, we have been successfully audited by the US FDA, the EMEA and the Japanese regulatory agencies.

Major Markets

WITH OVER 30 PRODUCTS LAUNCHED in 90 countries, Elan's Drug Technologies Group has a proven track record of delivering success. Key markets for which we have developed and manufactured products include the U.S. and Canada, all major markets in Europe, Japan and Asia Pacific Rim, as well as a number of markets in South America. Our facilities in Ireland and the U.S. meet FDA/EU/JMHLW GMP Guidelines and have been successfully audited by major regulatory agencies worldwide. Today, more than 2.5 million patients worldwide use drug products based on or enhanced by our technologies.

Services Offered

ELAN OFFERS THE INDUSTRY a suite of proprietary technology driven solutions. We have unrivalled expertise in formulation, development, scale-up and manufacture for proven and effective Drug Reformulation and Life Cycle Management Strategies.

- A Highly skilled work-force seasoned in product development—from feasibility through regulatory approval and product launch
- A Strong IP portfolio of more than 1,700 patents including extensive NanoCrystal® Technology and Oral Controlled Release patent estate
- Broad range of technology solutions from solubility enhancement to controlled release
- 39+ years experience in pharmaceutical product development
- 60,500 sq. ft. dedicated fully-equipped R&D facilities between U.S. and Ireland
- On-site tech transfer to commercial manufacturing
- Experience, proven track record, infrastructure and capacity in manufacturing
- 270,000 sq. ft. of cGMP manufacturing facility between U.S. and Ireland
- An Excellent compliance record
- DEA-approved Controlled Substance manufacturing plant in U.S.
- Sterile Fill Finish facilities
- A Mature infrastructure
- Development & tech transfer capabilities
- A focus on partnering with customers

www.elan.com/EDT

